Unique ID issued by UMIN | UMIN000013590 |
---|---|
Receipt number | R000015879 |
Scientific Title | The evaluation of the efficacy and safety of Hainosankyuto on purulence in patients with lymphedema |
Date of disclosure of the study information | 2014/05/07 |
Last modified on | 2018/01/29 09:20:27 |
The evaluation of the efficacy and safety of Hainosankyuto on purulence in patients with lymphedema
The effect of Hainosankyuto on purulence in patients with lymphedema
The evaluation of the efficacy and safety of Hainosankyuto on purulence in patients with lymphedema
The effect of Hainosankyuto on purulence in patients with lymphedema
Japan |
Patients with lymphedema
Medicine in general | Surgery in general | Obstetrics and Gynecology |
Dermatology |
Others
NO
To evaluate the efficacy and safety on purulence in patients with lymphedema and to explore the action mechanism by clinical pharmacological testing of Hainosankyuto
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
The number of days to clear the symptoms of purulence
1)The severity of the symptoms of purulence 2)The body temperature 3)QOL questionnaire 4)The circumference of the region of lymphedema (the affected side) 5)Immunologic test [Measuring NK cell activity, balance between Th1 and Th2, and cytokine (TNF-alpha, IL-12)]
Interventional
Parallel
Randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
TSUMURA Hainosankyuto Extract Granules for Ethical Use plus oral antibiotics for two weeks
oral antibiotics for two weeks
20 | years-old | <= |
75 | years-old | >= |
Female
1)Patients with lymphedema
2)Patients diagnosed grade 2 and more in lymphedema staging according to International Society of Lymphedema (ISL)
3)Patients with a first episode of purulence or who relapsed after over a year
4)Patients within 3 days after the onset of purulence
5)20-75 years of age
6)Sex: Female
7)Outpatient
8)Patients with written consent
1)Patients with aldosteronism, myopathy and hypokalemia
2)Patients who were prescribed Kampo medicine within 4 weeks before entry
3)Patients who were prescribed an adrenocortical hormonic agent or an anti-allergic agent
4)Patients with serious complications (liver, kidney, heart, blood, or metabolic disorders)
5)Patients with recurrent or metastasized cancer
6)Pregnant patients, breast-feeding patients or patients hoping to become pregnant
7)Patients considered inappropriate by the study investigator
20
1st name | |
Middle name | |
Last name | Noriaki Sakuragi |
Hokkaido University School of Medicine
Department of Obstetrics and Gynecology
North 15, West 7, Kitaku, Sapporo 060-8638, Japan
011-706-5941
sakuragi@med.hokudai.ac.jp
1st name | |
Middle name | |
Last name | Noriko Kobayashi |
Hokkaido University Hospital
Gynecology
North 15, West 7, Kitaku, Sapporo 060-8638, Japan
011-706-5941
norikingyo@med.hokudai.ac.jp
Hokkaido University School of Medicine
TSUMURA & CO.
Profit organization
NO
2014 | Year | 05 | Month | 07 | Day |
Unpublished
Completed
2014 | Year | 03 | Month | 25 | Day |
2014 | Year | 05 | Month | 07 | Day |
2014 | Year | 04 | Month | 01 | Day |
2018 | Year | 01 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015879
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |